Rhythm Pharmaceuticals price target raised to $105 from $92 at Canaccord

Canaccord raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $105 from $92 and keeps a Buy rating on the shares. The firm attended the Endocrine Society’s Annual Meeting where obesity remained the hottest topic and what’s coming up next in the pipeline and how to preserve (healthy/functional) lean muscle mass. Dr. Ashley Shoemaker stressed the importance of genetic testing for pediatric patients to a packed room and shared a link to Rhythm’s testing program.